Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (TW009338)
Harvard Catalyst (TR001100)
Harvard University Center for AIDS Research (5P30AI060354-13)
Received: 11 September 2017
Accepted: 4 March 2018
First Online: 27 March 2018
Ethics approval and consent to participate
: The research protocol for this study was approved by the Institutional Ethics Committee of the National Institute for Research in TB (NIRT) (FWA00005104) on December 29, 2014 and the Institutional Review Board of Brigham and Women’s Hospital (Partners Healthcare) (FWA00000484) on January 13, 2015. Informed consent for tracking of patients by the study team was waived by these committees, because patient tracking was conducted using RNTCP records, and phone calls and home visits were conducted in conjunction with RNTCP staff. Written informed consent was collected from all PTLFU patients who agreed to participate in the qualitative interviews.
: This manuscript does not contain any individual’s data in any form. Quantitative data were de-identified prior to analysis. The qualitative interview findings are not reported in this manuscript.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.